EyeGate Pharmaceuticals Lands $5,900,000 Series D Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=117b60fa-4155-4855-95ce-8fd6fa402d74&Preview=1
Date
1/6/2011
Company Name
EyeGate Pharmaceuticals
Mailing Address
100 Beaver Street Waltham, MA 02453
Company Description
EyeGate Pharma is focused on replacing ocular injections and other invasive methods of ocular disease treatment. Our goal is to build a pipeline of safer, more effective and patient friendly ocular treatments based on our EyeGate II Delivery System.
Website
http://www.eyegatepharma.com
Transaction Type
Venture Equity
Transaction Amount
$5,900,000
Transaction Round
Series D
Proceeds Purposes
The funds will be used to continue development of EGP-437 for the treatment of Dry EyeSyndrome (DES), an ocular surface irritation affecting several million men and women in theUnited States. EGP-437 is a dexamethasone derived corticosteroid solution speciallyformulated for delivery using the EyeGate® II Delivery System.
M&A Terms
Venture Investor
Undisclosed